Shelter Mutual Insurance Co cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,660 shares of the biopharmaceutical company’s stock after selling 5,840 shares during the quarter. Shelter Mutual Insurance Co’s holdings in Gilead Sciences were worth $4,099,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Creative Financial Designs Inc. ADV grew its holdings in shares of Gilead Sciences by 55.9% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares during the last quarter. Trustcore Financial Services LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at approximately $34,000. Weaver Consulting Group bought a new stake in shares of Gilead Sciences during the 1st quarter valued at approximately $34,000. Legacy Advisors LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at approximately $37,000. Finally, Founders Capital Management grew its holdings in shares of Gilead Sciences by 50.0% during the 1st quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 78.87% of the company’s stock.
GILD traded up $0.41 during trading on Thursday, reaching $63.53. 156,435 shares of the company’s stock were exchanged, compared to its average volume of 6,220,770. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $81.03 billion, a PE ratio of 10.35, a PEG ratio of 3.04 and a beta of 1.16. The stock has a fifty day moving average price of $66.33.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.97%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.
In related news, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the transaction, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,869,862.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the transaction, the executive vice president now owns 34,398 shares in the company, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
Several equities research analysts recently issued reports on GILD shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. Citigroup set a $78.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, July 31st. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a report on Friday, April 26th. They set an “outperform” rating and a $82.00 price target on the stock. Cowen reaffirmed a “buy” rating on shares of Gilead Sciences in a report on Friday, May 3rd. Finally, Morgan Stanley set a $82.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $82.29.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: Net Income
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.